Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03167619 · ClinicalTrials.gov registry record · Phase 2
Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT03167619 is a Phase 2 study that has completed, run by Duke University. The registered enrollment target is 45 participants.
The verdict
NCT03167619, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This is a randomized, international, multicenter, Phase II study designed to explore the efficacy of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC. The primary objectives are to explore olaparib or olaparib in combination with durvalumab as maintenance therapy following clinical benefit with platinum-based therapy in subjects with mTNBC.
Interventions
- DRUG Olaparib Oral Product
- DRUG Olaparib Oral Product in combination with Durvalumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03167619
The ClinicalTrials.gov registry entry for NCT03167619 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olaparib Oral Product is the first listed.
NCT03167619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03167619 about?
NCT03167619 is a clinical study titled "Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA)". This is a randomized, international, multicenter, Phase II study designed to explore the efficacy of olaparib or olaparib in combination with durvalumab in platinum-treated mTNBC. The primary objectives are to explore olaparib or olaparib in combination with durvalumab as maintenance therapy followi...
What is the current status of trial NCT03167619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2018-10-04. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03167619?
The interventions under investigation include: Olaparib Oral Product (DRUG), Olaparib Oral Product in combination with Durvalumab (DRUG).
Who is sponsoring clinical trial NCT03167619?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.